{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T15:07:29Z","timestamp":1794928049229,"version":"4.9.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cancer cells have a characteristic metabolism, mostly caused by alterations in signal transduction networks rather than mutations in metabolic enzymes. For metabolic drugs to be cancer-selective, signaling alterations need to be identified that confer a druggable vulnerability. Here, we demonstrate that many tumor cells with an acquired cancer drug resistance exhibit increased sensitivity to mechanistically distinct inhibitors of cancer metabolism. We demonstrate that this metabolic vulnerability is driven by mTORC1, which promotes resistance to chemotherapy and targeted cancer drugs, but simultaneously suppresses autophagy. We show that autophagy is essential for tumor cells to cope with therapeutic perturbation of metabolism and that mTORC1-mediated suppression of autophagy is required and sufficient for generating a metabolic vulnerability leading to energy crisis and apoptosis. Our study links mTOR-induced cancer drug resistance to autophagy defects as a cause of a metabolic liability and opens a therapeutic window for the treatment of otherwise therapy-refractory tumor patients.<\/jats:p>","DOI":"10.1038\/s41467-020-18504-7","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T17:28:45Z","timestamp":1600363725000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":172,"title":["mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability"],"prefix":"10.1038","volume":"11","author":[{"given":"Niklas","family":"Gremke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierfrancesco","family":"Polo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Dort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Schneikert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Elmsh\u00e4user","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Brehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Klingm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Christian","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3114-6403","authenticated-orcid":false,"given":"Oleg","family":"Timofeev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wanzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0134-7826","authenticated-orcid":false,"given":"Thorsten","family":"Stiewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,17]]},"reference":[{"key":"18504_CR1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack, I. & Shaw, A. T. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol. 15, 81\u201394 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"18504_CR2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrclinonc.2017.198","volume":"15","author":"L Sansregret","year":"2018","unstructured":"Sansregret, L., Vanhaesebroeck, B. & Swanton, C. Determinants and clinical implications of chromosomal instability in cancer. Nat. Rev. Clin. Oncol. 15, 139\u2013150 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"18504_CR3","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41568-018-0056-x","volume":"18","author":"NK Lytle","year":"2018","unstructured":"Lytle, N. K., Barber, A. G. & Reya, T. Stem cell fate in cancer growth, progression and therapy resistance. Nat. Rev. Cancer 18, 669\u2013680 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"18504_CR4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.trecan.2016.03.008","volume":"2","author":"E Ilagan","year":"2016","unstructured":"Ilagan, E. & Manning, B. D. Emerging role of mTOR in the response to cancer therapeutics. Trends Cancer 2, 241\u2013251 (2016).","journal-title":"Trends Cancer"},{"key":"18504_CR5","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.trecan.2016.10.006","volume":"2","author":"Y Guri","year":"2016","unstructured":"Guri, Y. & Hall, M. N. mTOR signaling confers resistance to targeted cancer drugs. Trends Cancer 2, 688\u2013697 (2016).","journal-title":"Trends Cancer"},{"key":"18504_CR6","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. Cell 168, 960\u2013976 (2017).","journal-title":"Cell"},{"key":"18504_CR7","doi-asserted-by":"crossref","unstructured":"Liu, G. Y. & Sabatini, D. M. mTOR at the nexus of nutrition, growth, ageing and disease. Nat. Rev. Mol. Cell Biol. 21, 246 (2020).","DOI":"10.1038\/s41580-020-0219-y"},{"key":"18504_CR8","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.cmet.2017.04.004","volume":"25","author":"AC Kimmelman","year":"2017","unstructured":"Kimmelman, A. C. & White, E. Autophagy and tumor metabolism. Cell Metab. 25, 1037\u20131043 (2017).","journal-title":"Cell Metab."},{"key":"18504_CR9","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1126\/science.1196371","volume":"331","author":"DF Egan","year":"2011","unstructured":"Egan, D. F. et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 331, 456\u2013461 (2011).","journal-title":"Science"},{"key":"18504_CR10","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/ncb2152","volume":"13","author":"J Kim","year":"2011","unstructured":"Kim, J., Kundu, M., Viollet, B. & Guan, K. L. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 13, 132\u2013141 (2011).","journal-title":"Nat. Cell Biol."},{"key":"18504_CR11","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-13-0353","volume":"4","author":"N Wagle","year":"2014","unstructured":"Wagle, N. et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 4, 546\u2013553 (2014).","journal-title":"Cancer Discov."},{"key":"18504_CR12","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/2159-8290.CD-13-0929","volume":"4","author":"BC Grabiner","year":"2014","unstructured":"Grabiner, B. C. et al. A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov. 4, 554\u2013563 (2014).","journal-title":"Cancer Discov."},{"key":"18504_CR13","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.celrep.2014.04.014","volume":"7","author":"V Pirazzoli","year":"2014","unstructured":"Pirazzoli, V. et al. Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. Cell Rep. 7, 999\u20131008 (2014).","journal-title":"Cell Rep."},{"key":"18504_CR14","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/j.celrep.2014.05.039","volume":"7","author":"S Kawabata","year":"2014","unstructured":"Kawabata, S. et al. Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M. Cell Rep. 7, 1824\u20131832 (2014).","journal-title":"Cell Rep."},{"key":"18504_CR15","doi-asserted-by":"crossref","first-page":"196ra199","DOI":"10.1126\/scitranslmed.3005747","volume":"5","author":"M Elkabets","year":"2013","unstructured":"Elkabets, M. et al. mTORC1 inhibition is required for sensitivity to PI3K p110alpha inhibitors in PIK3CA-mutant breast cancer. Sci. Transl. Med. 5, 196ra199 (2013).","journal-title":"Sci. Transl. Med."},{"key":"18504_CR16","doi-asserted-by":"crossref","first-page":"196ra198","DOI":"10.1126\/scitranslmed.3005753","volume":"5","author":"RB Corcoran","year":"2013","unstructured":"Corcoran, R. B. et al. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci. Transl. Med. 5, 196ra198 (2013).","journal-title":"Sci. Transl. Med."},{"key":"18504_CR17","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1158\/0008-5472.CAN-12-4282","volume":"73","author":"C Shen","year":"2013","unstructured":"Shen, C. et al. Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks. Cancer Res. 73, 3393\u20133401 (2013).","journal-title":"Cancer Res."},{"key":"18504_CR18","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1038\/leu.2013.93","volume":"27","author":"F Guo","year":"2013","unstructured":"Guo, F. et al. mTOR regulates DNA damage response through NF-kappaB-mediated FANCD2 pathway in hematopoietic cells. Leukemia 27, 2040\u20132046 (2013).","journal-title":"Leukemia"},{"key":"18504_CR19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nchembio.1965","volume":"12","author":"M Wanzel","year":"2016","unstructured":"Wanzel, M. et al. CRISPR-Cas9-based target validation for p53-reactivating model compounds. Nat. Chem. Biol. 12, 22\u201328 (2016).","journal-title":"Nat. Chem. Biol."},{"key":"18504_CR20","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.bbamcr.2018.06.011","volume":"1865","author":"Y Ma","year":"2018","unstructured":"Ma, Y., Vassetzky, Y. & Dokudovskaya, S. mTORC1 pathway in DNA damage response. Biochim Biophys. Acta Mol. Cell Res. 1865, 1293\u20131311 (2018).","journal-title":"Biochim Biophys. Acta Mol. Cell Res."},{"key":"18504_CR21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","volume":"15","author":"F Janku","year":"2018","unstructured":"Janku, F., Yap, T. A. & Meric-Bernstam, F. Targeting the PI3K pathway in cancer: are we making headway? Nat. Rev. Clin. Oncol. 15, 273\u2013291 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"18504_CR22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s42255-019-0038-7","volume":"1","author":"AJ Valvezan","year":"2019","unstructured":"Valvezan, A. J. & Manning, B. D. Molecular logic of mTORC1 signalling as a metabolic rheostat. Nat. Metab. 1, 321\u2013333 (2019).","journal-title":"Nat. Metab."},{"key":"18504_CR23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2007.10.002","volume":"7","author":"RJ DeBerardinis","year":"2008","unstructured":"DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G. & Thompson, C. B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7, 11\u201320 (2008).","journal-title":"Cell Metab."},{"key":"18504_CR24","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","volume":"168","author":"MG Vander Heiden","year":"2017","unstructured":"Vander Heiden, M. G. & DeBerardinis, R. J. Understanding the intersections between metabolism and cancer biology. Cell 168, 657\u2013669 (2017).","journal-title":"Cell"},{"key":"18504_CR25","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"18504_CR26","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd3504","volume":"10","author":"MG Vander Heiden","year":"2011","unstructured":"Vander Heiden, M. G. Targeting cancer metabolism: a therapeutic window opens. Nat. Rev. Drug Discov. 10, 671\u2013684 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"18504_CR27","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.chembiol.2017.08.028","volume":"24","author":"A Luengo","year":"2017","unstructured":"Luengo, A., Gui, D. Y. & Vander Heiden, M. G. Targeting metabolism for cancer therapy. Cell Chem. Biol. 24, 1161\u20131180 (2017).","journal-title":"Cell Chem. Biol."},{"key":"18504_CR28","first-page":"485","volume":"21","author":"BR Landau","year":"1958","unstructured":"Landau, B. R., Laszlo, J., Stengle, J. & Burk, D. Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-D-glucose. J. Natl. Cancer Inst. 21, 485\u2013494 (1958).","journal-title":"J. Natl. Cancer Inst."},{"key":"18504_CR29","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/pros.21172","volume":"70","author":"M Stein","year":"2010","unstructured":"Stein, M. et al. Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate 70, 1388\u20131394 (2010).","journal-title":"Prostate"},{"key":"18504_CR30","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00280-012-2045-1","volume":"71","author":"LE Raez","year":"2013","unstructured":"Raez, L. E. et al. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 71, 523\u2013530 (2013).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"18504_CR31","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00432-014-1583-9","volume":"140","author":"EB Garon","year":"2014","unstructured":"Garon, E. B. et al. Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 140, 443\u2013452 (2014).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"18504_CR32","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms4981","volume":"5","author":"JP Charles","year":"2014","unstructured":"Charles, J. P. et al. Monitoring the dynamics of clonal tumour evolution in vivo using secreted luciferases. Nat. Commun. 5, 3981 (2014).","journal-title":"Nat. Commun."},{"key":"18504_CR33","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.cell.2015.05.053","volume":"162","author":"F Dietlein","year":"2015","unstructured":"Dietlein, F. et al. A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer. Cell 162, 146\u2013159 (2015).","journal-title":"Cell"},{"key":"18504_CR34","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1101\/gad.195248.112","volume":"26","author":"H Kim","year":"2012","unstructured":"Kim, H. & D\u2019Andrea, A. D. Regulation of DNA cross-link repair by the Fanconi anemia\/BRCA pathway. Genes Dev. 26, 1393\u20131408 (2012).","journal-title":"Genes Dev."},{"key":"18504_CR35","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41388-018-0479-6","volume":"38","author":"SQ Liang","year":"2019","unstructured":"Liang, S. Q. et al. mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer. Oncogene 38, 622\u2013636 (2019).","journal-title":"Oncogene"},{"key":"18504_CR36","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","volume":"7","author":"L Kelland","year":"2007","unstructured":"Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 7, 573\u2013584 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"18504_CR37","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/0008-5472.CAN-09-1751","volume":"70","author":"CM Chresta","year":"2010","unstructured":"Chresta, C. M. et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 70, 288\u2013298 (2010).","journal-title":"Cancer Res."},{"key":"18504_CR38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1172\/JCI73939","volume":"125","author":"YC Kim","year":"2015","unstructured":"Kim, Y. C. & Guan, K. L. mTOR: a pharmacologic target for autophagy regulation. J. Clin. Invest. 125, 25\u201332 (2015).","journal-title":"J. Clin. Invest."},{"key":"18504_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15548627.2015.1100356","volume":"12","author":"DJ Klionsky","year":"2016","unstructured":"Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12, 1\u2013222 (2016).","journal-title":"Autophagy"},{"key":"18504_CR40","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1021\/acschembio.7b00549","volume":"13","author":"MK Schwinn","year":"2018","unstructured":"Schwinn, M. K. et al. CRISPR-mediated tagging of endogenous proteins with a luminescent peptide. ACS Chem. Biol. 13, 467\u2013474 (2018).","journal-title":"ACS Chem. Biol."},{"key":"18504_CR41","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ccr.2011.03.012","volume":"19","author":"JH Sheen","year":"2011","unstructured":"Sheen, J. H., Zoncu, R., Kim, D. & Sabatini, D. M. Defective regulation of autophagy upon leucine deprivation reveals a targetable liability of human melanoma cells in vitro and in vivo. Cancer Cell 19, 613\u2013628 (2011).","journal-title":"Cancer Cell"},{"key":"18504_CR42","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1128\/MCB.06159-11","volume":"32","author":"S Alers","year":"2012","unstructured":"Alers, S., Loffler, A. S., Wesselborg, S. & Stork, B. Role of AMPK-mTOR-Ulk1\/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks. Mol. Cell. Biol. 32, 2\u201311 (2012).","journal-title":"Mol. Cell. Biol."},{"key":"18504_CR43","doi-asserted-by":"crossref","unstructured":"Heckmann, B. L. & Green, D. R. LC3-associated phagocytosis at a glance. J. Cell Sci. 132, jcs222984 (2019).","DOI":"10.1242\/jcs.222984"},{"key":"18504_CR44","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/ncb3192","volume":"17","author":"J Martinez","year":"2015","unstructured":"Martinez, J. et al. Molecular characterization of LC3-associated phagocytosis reveals distinct roles for Rubicon, NOX2 and autophagy proteins. Nat. Cell Biol. 17, 893\u2013906 (2015).","journal-title":"Nat. Cell Biol."},{"key":"18504_CR45","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1042\/bst0311165","volume":"31","author":"RM Mayers","year":"2003","unstructured":"Mayers, R. M. et al. AZD7545, a novel inhibitor of pyruvate dehydrogenase kinase 2 (PDHK2), activates pyruvate dehydrogenase in vivo and improves blood glucose control in obese (fa\/fa) Zucker rats. Biochem. Soc. Trans. 31, 1165\u20131167 (2003).","journal-title":"Biochem. Soc. Trans."},{"key":"18504_CR46","first-page":"683","volume":"15","author":"F Zi","year":"2018","unstructured":"Zi, F. et al. Metformin and cancer: an existing drug for cancer prevention and therapy. Oncol. Lett. 15, 683\u2013690 (2018).","journal-title":"Oncol. Lett."},{"key":"18504_CR47","doi-asserted-by":"crossref","first-page":"e02242","DOI":"10.7554\/eLife.02242","volume":"3","author":"WW Wheaton","year":"2014","unstructured":"Wheaton, W. W. et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife 3, e02242 (2014).","journal-title":"Elife"},{"key":"18504_CR48","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nrclinonc.2017.1","volume":"14","author":"UE Martinez-Outschoorn","year":"2017","unstructured":"Martinez-Outschoorn, U. E., Peiris-Pages, M., Pestell, R. G., Sotgia, F. & Lisanti, M. P. Cancer metabolism: a therapeutic perspective. Nat. Rev. Clin. Oncol. 14, 113 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"18504_CR49","doi-asserted-by":"crossref","first-page":"pe31","DOI":"10.1126\/scisignal.2004632","volume":"6","author":"I Kelsey","year":"2013","unstructured":"Kelsey, I. & Manning, B. D. mTORC1 status dictates tumor response to targeted therapeutics. Sci. Signal. 6, pe31 (2013).","journal-title":"Sci. Signal."},{"key":"18504_CR50","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/nm1146","volume":"10","author":"N Issaeva","year":"2004","unstructured":"Issaeva, N. et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 10, 1321\u20131328 (2004).","journal-title":"Nat. Med."},{"key":"18504_CR51","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1126\/science.1232044","volume":"340","author":"L Bar-Peled","year":"2013","unstructured":"Bar-Peled, L. et al. A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science 340, 1100\u20131106 (2013).","journal-title":"Science"},{"key":"18504_CR52","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1535-6108(02)00104-6","volume":"2","author":"ML Nickerson","year":"2002","unstructured":"Nickerson, M. L. et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2, 157\u2013164 (2002).","journal-title":"Cancer Cell"},{"key":"18504_CR53","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1172\/JCI67841","volume":"123","author":"MC Caino","year":"2013","unstructured":"Caino, M. C. et al. Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells. J. Clin. Invest. 123, 2907\u20132920 (2013).","journal-title":"J. Clin. Invest."},{"key":"18504_CR54","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1083\/jcb.200507002","volume":"171","author":"G Bjorkoy","year":"2005","unstructured":"Bjorkoy, G. et al. p62\/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J. Cell Biol. 171, 603\u2013614 (2005).","journal-title":"J. Cell Biol."},{"key":"18504_CR55","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14423","volume":"8","author":"JR Delaney","year":"2017","unstructured":"Delaney, J. R. et al. Haploinsufficiency networks identify targetable patterns of allelic deficiency in low mutation ovarian cancer. Nat. Commun. 8, 14423 (2017).","journal-title":"Nat. Commun."},{"key":"18504_CR56","doi-asserted-by":"crossref","first-page":"e1008558","DOI":"10.1371\/journal.pgen.1008558","volume":"16","author":"JR Delaney","year":"2020","unstructured":"Delaney, J. R. et al. Autophagy gene haploinsufficiency drives chromosome instability, increases migration, and promotes early ovarian tumors. PLoS Genet. 16, e1008558 (2020).","journal-title":"PLoS Genet."},{"key":"18504_CR57","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/B978-0-12-801329-8.00009-X","volume":"543","author":"M Pietzke","year":"2014","unstructured":"Pietzke, M. & Kempa, S. Pulsed stable isotope-resolved metabolomic studies of cancer cells. Methods Enzymol. 543, 179\u2013198 (2014).","journal-title":"Methods Enzymol."},{"key":"18504_CR58","first-page":"617","volume":"1846","author":"S Kankotia","year":"2014","unstructured":"Kankotia, S. & Stacpoole, P. W. Dichloroacetate and cancer: new home for an orphan drug? Biochim. Biophys. Acta 1846, 617\u2013629 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"18504_CR59","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1042\/BJ20140620","volume":"462","author":"HR Bridges","year":"2014","unstructured":"Bridges, H. R., Jones, A. J., Pollak, M. N. & Hirst, J. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem. J. 462, 475\u2013487 (2014).","journal-title":"Biochem. J."},{"key":"18504_CR60","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1042\/bj3480607","volume":"348","author":"MR Owen","year":"2000","unstructured":"Owen, M. R., Doran, E. & Halestrap, A. P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348, 607\u2013614 (2000). Pt 3.","journal-title":"Biochem. J."},{"key":"18504_CR61","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1074\/jbc.275.1.223","volume":"275","author":"MY El-Mir","year":"2000","unstructured":"El-Mir, M. Y. et al. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 275, 223\u2013228 (2000).","journal-title":"J. Biol. Chem."},{"key":"18504_CR62","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.cmet.2016.09.006","volume":"24","author":"DY Gui","year":"2016","unstructured":"Gui, D. Y. et al. Environment dictates dependence on mitochondrial complex i for NAD+ and aspartate production and determines cancer cell sensitivity to metformin. Cell Metab. 24, 716\u2013727 (2016).","journal-title":"Cell Metab."},{"key":"18504_CR63","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cmet.2015.01.003","volume":"21","author":"L He","year":"2015","unstructured":"He, L. & Wondisford, F. E. Metformin action: concentrations matter. Cell Metab. 21, 159\u2013162 (2015).","journal-title":"Cell Metab."},{"key":"18504_CR64","doi-asserted-by":"crossref","DOI":"10.1186\/s12915-014-0082-4","volume":"12","author":"A Luengo","year":"2014","unstructured":"Luengo, A., Sullivan, L. B. & Heiden, M. G. Understanding the complex-I-ty of metformin action: limiting mitochondrial respiration to improve cancer therapy. BMC Biol. 12, 82 (2014).","journal-title":"BMC Biol."},{"key":"18504_CR65","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/bjc.2012.56","volume":"106","author":"MV Appleyard","year":"2012","unstructured":"Appleyard, M. V. et al. Phenformin as prophylaxis and therapy in breast cancer xenografts. Br. J. Cancer 106, 1117\u20131122 (2012).","journal-title":"Br. J. Cancer"},{"key":"18504_CR66","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40170-015-0138-0","volume":"3","author":"L Schockel","year":"2015","unstructured":"Schockel, L. et al. Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth. Cancer Metab. 3, 11 (2015).","journal-title":"Cancer Metab."},{"key":"18504_CR67","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.1158\/1078-0432.CCR-17-1115","volume":"23","author":"NV Rajeshkumar","year":"2017","unstructured":"Rajeshkumar, N. V. et al. Treatment of pancreatic cancer patient-derived xenograft panel with metabolic inhibitors reveals efficacy of phenformin. Clin. Cancer Res. 23, 5639\u20135647 (2017).","journal-title":"Clin. Cancer Res."},{"key":"18504_CR68","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1101\/gad.283416.116","volume":"30","author":"JY Guo","year":"2016","unstructured":"Guo, J. Y. et al. Autophagy provides metabolic substrates to maintain energy charge and nucleotide pools in Ras-driven lung cancer cells. Genes Dev. 30, 1704\u20131717 (2016).","journal-title":"Genes Dev."},{"key":"18504_CR69","first-page":"4294","volume":"72","author":"YL Hu","year":"2012","unstructured":"Hu, Y. L., Jahangiri, A., Delay, M. & Aghi, M. K. Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapy. Cancer Res. 72, 4294\u20134299 (2012).","journal-title":"Cancer Res."},{"key":"18504_CR70","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nrclinonc.2016.183","volume":"14","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi, L., Bravo-San Pedro, J. M., Demaria, S., Formenti, S. C. & Kroemer, G. Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy. Nat. Rev. Clin. Oncol. 14, 247\u2013258 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"18504_CR71","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41580-018-0003-4","volume":"19","author":"I Dikic","year":"2018","unstructured":"Dikic, I. & Elazar, Z. Mechanism and medical implications of mammalian autophagy. Nat. Rev. Mol. Cell Biol. 19, 349\u2013364 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"18504_CR72","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2011.86","volume":"2","author":"T Tomic","year":"2011","unstructured":"Tomic, T. et al. Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis. 2, e199 (2011).","journal-title":"Cell Death Dis."},{"key":"18504_CR73","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1158\/1535-7163.MCT-11-0497","volume":"10","author":"JH Cheong","year":"2011","unstructured":"Cheong, J. H. et al. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol. Cancer Ther. 10, 2350\u20132362 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"18504_CR74","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/carcin\/bgz036","volume":"40","author":"N Castelletti","year":"2019","unstructured":"Castelletti, N. et al. Risk of lung adenocarcinoma from smoking and radiation arises in distinct molecular pathways. Carcinogenesis 40, 1240\u20131250 (2019).","journal-title":"Carcinogenesis"},{"key":"18504_CR75","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1158\/1078-0432.CCR-17-2961","volume":"24","author":"HA Yu","year":"2018","unstructured":"Yu, H. A. et al. Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance. Clin. Cancer Res. 24, 3108\u20133118 (2018).","journal-title":"Clin. Cancer Res."},{"key":"18504_CR76","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41568-018-0074-8","volume":"18","author":"D Mossmann","year":"2018","unstructured":"Mossmann, D., Park, S. & Hall, M. N. mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat. Rev. Cancer 18, 744\u2013757 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"18504_CR77","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1126\/science.1157535","volume":"320","author":"Y Sancak","year":"2008","unstructured":"Sancak, Y. et al. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320, 1496\u20131501 (2008).","journal-title":"Science"},{"key":"18504_CR78","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1073\/pnas.1008322108","volume":"108","author":"K Yusa","year":"2011","unstructured":"Yusa, K., Zhou, L., Li, M. A., Bradley, A. & Craig, N. L. A hyperactive piggyBac transposase for mammalian applications. Proc. Natl. Acad. Sci. USA 108, 1531\u20131536 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"18504_CR79","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nmeth.1177","volume":"5","author":"T Wurdinger","year":"2008","unstructured":"Wurdinger, T. et al. A secreted luciferase for ex vivo monitoring of in vivo processes. Nat. Methods 5, 171\u2013173 (2008).","journal-title":"Nat. Methods"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18504-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18504-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18504-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T19:57:44Z","timestamp":1670270264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-18504-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,17]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["18504"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-18504-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,17]]},"assertion":[{"value":"26 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4684"}}